Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
70 hedge funds and large institutions have $116M invested in Stemline Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 15 closing their positions.
204% more call options, than puts
Call options by funds: $1.75M | Put options by funds: $575K
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
2% less capital invested
Capital invested by funds: $119M → $116M (-$2.84M)
7% less funds holding
Funds holding: 75 → 70 (-5)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
+$1.63M |
| 2 |
AG
Artal Group
Luxembourg
|
+$1.25M |
| 3 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$1.05M |
| 4 |
CCI
Columbus Circle Investors
|
+$1.05M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$12.4M |
| 2 |
VMI
VHCP Management II
New York
|
-$1.95M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$1.92M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$855K |
| 5 |
Millennium Management
New York
|
-$714K |
STML Hedge Fund Activity: Q2 2017 in Review
70 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2017, worth a combined $116M — down 2.4% from $119M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of STML and 10 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 22 added.
The largest buyer was Axa, adding an estimated $1.63M. The largest seller was Franklin Resources, exiting entirely with an estimated $12.4M sold.
- 70 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2017, down from 75 in Q1 2017.
- Funds reported $116M of Stemline Therapeutics, Inc. stock for Q2 2017, down 2.4% quarter-over-quarter.
- 10 funds opened new Stemline Therapeutics, Inc. positions in Q2 2017 and 15 closed out, a net change of -5 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q2 2017 was Axa, an estimated $1.63M added.
- The largest Stemline Therapeutics, Inc. seller in Q2 2017 was Franklin Resources, an estimated $12.4M sold.
Based on aggregated 13F filings for Q2 2017.